Hypermarcas (OTCMKTS:HYPMY) Stock Short Interest Report for October

Hypermarcas (OTCMKTS:HYPMY) was the target of a significant drop in short interest during the month of October. As of October 15th, there was short interest totaling 1,675 shares, a drop of 60.7% from the September 30th total of 4,266 shares. Based on an average trading volume of 1,020,623 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company’s shares are short sold.

Hypermarcas Price Performance

HYPMY opened at $4.01 on Thursday. Hypermarcas has a 52 week low of $3.39 and a 52 week high of $5.77. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.26 and a current ratio of 1.86. The firm has a market capitalization of $2.82 billion, a PE ratio of 8.02 and a beta of 0.65. The company has a fifty day moving average price of $4.66 and a two-hundred day moving average price of $4.44.

Hypermarcas (OTCMKTS:HYPMY) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.01. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. As a group, analysts anticipate that Hypermarcas will post 0.51 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group raised Hypermarcas to a “strong-buy” rating in a report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy”.

About Hypermarcas

Hypermarcas SA was a Brazilian consumer-health and pharmaceutical company that later changed its corporate name to Hypera SA The company was established as a diversified consumer-products business and, over time, shifted its focus toward pharmaceuticals and healthcare products.

Hypera develops, manufactures and markets prescription medicines, generic and branded-generic drugs, over-the-counter products, vitamins and nutritional supplements. Its portfolio has included well-known Brazilian consumer-health brands such as Neosaldina, Doril, Engov, Benegrip and Addera D3, serving categories including pain relief, cold and flu treatment, digestive health and vitamins.

The company’s principal market is Brazil, where its products are distributed through pharmacies, retailers and other healthcare channels.